title: Tacrolimus is highly effective in both dual and triple therapy regimens following renal transplantation. Spanish and Italian Tacrolimus Study Group.
abstract: This open, multicenter, randomized, parallel-group study evaluated the efficacy and safety of tacrolimus-based dual and triple therapy regimens. For this 3-month study (with 12-month follow up), 491 adult renal transplant patients were randomized and received either dual therapy (tacrolimus/corticosteroids; 246 patients) or triple therapy (tacrolimus/corticosteroids/azathioprine; 245 patients). Patient survival rates at months 3 and 12 were 99.2 (dual) vs 99.6% (triple) and 97.8 vs 98.7%, respectively. Graft survival rates at months 3 and 12 were 94.1 (dual) vs 95.4% (triple) and 92.8 vs 93.3%, respectively. After 3 months, the incidences of treated acute rejection were 28.8 (dual) and 29.7% (triple); and 7.6 (dual) and 5.4% (triple) for corticosteroid-resistant acute rejections. Between months 4 and 12, three new first rejections were reported, (dual: 2, triple: 1). For leukopenia (1.3 vs 11.7%; P < 0.001) and anemia (14.8 vs 23.0%, P = 0.026), significantly higher incidences were reported in the triple therapy group. The incidence of de novo insulin-dependent diabetes was 5.6 (dual) and 4.0% (triple) at month 3. In terms of efficacy, no difference between the treatment groups was observed.
authors: Azienda Ospedaliera S. Giovanni Battista, Divisione di Nefrologia e Dialisi, Turin, Italy. guiseppe.seguloni@unito.it
authors: G
authors: G
authors: Segoloni
authors: V
authors: V
authors: Bonomini
authors: M C
authors: MC
authors: Maresca
authors: L
authors: L
authors: Arisi
authors: M
authors: M
authors: Gonzalez-Molina
authors: A
authors: A
authors: Tarantino
authors: D
authors: D
authors: del Castillo
authors: J
authors: J
authors: Ortuño
authors: M
authors: M
authors: Carmellini
authors: L
authors: L
authors: Capdevila
authors: M
authors: M
authors: Arias
authors: J
authors: J
authors: Garcia
authors: P
authors: P
authors: Rigotti
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015994:Incidence; D007558:Italy; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D012086:Reoperation; D013030:Spain; D015996:Survival Rate; D016559:Tacrolimus / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus